| Catalog No. | Size | Price (USD) |
| 90311-C02H-1 | 1 mg | $3,730.91 |
| 90311-C02H-50 | 50 µg | $342.14 |
| 90311-C02H-100 | 100 µg | $573.19 |
General Information
| Formulation | Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Endotoxin | < 1.0 EU per μg protein as determined by the LAL method. |
| Shipping | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
| Stability & Storage | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution | To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA. |
| Purity | > 95 % as determined by SDS-PAGE |
| Activity | 1. Measured by its ability to bind PD-L1 Protein, Human, Recombinant (ECD, His Tag) (Cat:10084-H08H) in a functional ELISA. 2. Immobilized Cynomolgus / Rhesus PD-L1 / B7-H1 / CD274 Protein (His Tag) (Cat:90251-C08H) at 2 μg/mL (100 μL/well) can bind PD-1 Protein, Cynomolgus, Recombinant (hFc Tag) (Cat:90311-C02H), the EC 50 is 150-780 ng/mL. 3. Immobilized PD-1 Protein, Cynomolgus, Recombinant (hFc Tag)(Cat:90311-C02H) at 2 μg/mL (100 μL/well) can bind Anti-PD1(MDX)-IgG4 Antibody (Nivolumab)(Cat:68050-H001),the EC 50 is 8-50ng/mL. 4.Recombinant Cynomolgus PD-1 Protein, hFc Tag (Cat. No. 90311-C02H) captured on Protein A chip, can bind Biotinylated Recombinant Cynomolgus, Rhesus PD-L1/B7-H1 Protein, His & AVI Tag (Cat. No. 90251-C49H-B) with an affinity constant of 2.890 μM as determined in an SPR assay (Biacore 8K) (Routinely tested). 5.Loaded Recombinant Cynomolgus PD-1 Protein (hFc Tag) (Cat. No. 90311-C02H) on proA Biosensor, can bind Cynomolgus / Rhesus PD-L1 / B7-H1 / CD274 Protein (His Tag) (Cat. No. 90251-C08H) with an affinity constant of 5.140 μM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). 6.Loaded Recombinant Cynomolgus PD-1 Protein (hFc Tag) (Cat. No. 90311-C02H) on proA Biosensor, can bind Recombinant Cynomolgus, Rhesus PD-L2/B7-DC Protein(His Tag) (Cat. No. 90249-K08H) with an affinity constant of 0.310 μM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). |
| Protein Construction | A DNA sequence encoding the cynomolgus PDCD1 (B0LAJ3) (Met1-Gln167) was expressed with the Fc region of human IgG1 at the C-terminus. |
| Accession# | B0LAJ3 |
| Expressed Host | HEK293 Cells |
| Species | Cynomolgus |
| Predicted N Terminal | Leu 25 |
| Molecule Mass | The recombinant cynomolgus PDCD1 consists 381 amino acids and predicts a molecular mass of 42.7 kDa. |
Image / Experimental Information
| Image 1 Alt Text | Cynomolgus PD1/PDCD1/CD279 Protein 12961 |
| Image 1 URL | Source image |
| Image 2 Alt Text | Cynomolgus PD-1 Protein 33992 |
| Image 2 URL | Source image |
| Image 3 Alt Text | Cynomolgus PD-1 Protein 33995 |
| Image 3 URL | Source image |
| Image 4 Alt Text | Cynomolgus, Rhesus PD-L1/B7-H1 Protein 43541 |
| Image 4 URL | Source image |
| Image 5 Alt Text | Cynomolgus PD-1 Protein 45900 |
| Image 5 URL | Source image |
Background Information
| Full Name | programmed cell death 1 |
| Description | Programmed cell death 1, also known as PDCD1, is a type I transmembrane glycoprotein, and is an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. PD1 has been suggested to be involved in lymphocyte clonal selection and peripheral tolerance, and thus contributes to the prevention of autoimmune diseases. Furthermore, PD1 is shown to be a regulator of virus-specific CD8+ T cell survival in HIV infection. As a cell surface molecule, PDCD1 regulates the adaptive immune response. Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function. |
| Research Areas |
|
| Tags |
|
| References |
|
title: Anti-PD-L1 antibody and use thereof
authors: Bohua Li; Huajing Wang; Xiaowen He
date: 2024-08-06
cited_by_count: 0
techniques: Binding Assay; Blocking Assay; Labeling; Recombinant
bioz_score: 93
title: Anti-PD-1 antibodies
authors: Yunying Chen; Jing Li
date: 2024-07-09
cited_by_count: 0
techniques: Control; Expressing; Modification; Purification; Recombinant; Synthesized
bioz_score: 93
title: Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
authors: Hassan Issafras; Shilong Fan; ...; Irina V. Balalaeva
journal: PLoS ONE
date: 2021-12-31
pmid: 34972111
doi: 10.1371/journal.pone.0257972
pmcid: 8719770
cited_by_count: 27
techniques: Activity Assay; Binding Assay; Blocking Assay; Clone Assay; Concentration Assay; Enzyme-linked Immunosorbent Assay; Expressing; Flow Cytometry; In Vitro; Luciferase; Mutagenesis; Negative Control; Plasmid Preparation; Positive Control; Purification; Recombinant; Reporter Assay; Staining; Transfection
bioz_score: 93
title: Anti-PD-1 antibody and use thereof
authors: Qiang Li; Yuncheng Zheng; ...; Yuanli Li
date: 2021-11-02
cited_by_count: 0
techniques: Blocking Assay; Incubation
bioz_score: 93
title: Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Non-Human Primates of the Anti-PD-1 Antibody Pembrolizumab
authors: Beth Hutchins; Gary C Starling; ...; Andrea van Elsas
journal: Molecular Cancer Therapeutics
date: 2020-03-30
doi: 10.1158/1535-7163.mct-19-0774
cited_by_count: 7
techniques: Exclusion Assay; Incubation; Injection; SPR Assay
bioz_score: 93
title: Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab
authors: Beth Hutchins; Gary C. Starling; ...; Andrea van Elsas
journal: Molecular Cancer Therapeutics
date: 2020-03-30
doi: 10.1158/1535-7163.mct-19-0774
cited_by_count: 7
techniques: Exclusion Assay; Incubation; Injection; Recombinant; SPR Assay
bioz_score: 93
title: Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
authors: Kimberly Ann Tipton; James William West; Chanty Mariategue Chan
date: 2019-12-24
cited_by_count: 0
techniques: Binding Assay; Enzyme-linked Immunosorbent Assay; Inhibition
bioz_score: 93
